Skip to main content
    O

    Olema Pharmaceuticals Inc (OLMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.36
    -0.20 (-2.65%)

    Market Cap: $662.30M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Olema Pharmaceuticals Inc (OLMA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Olema Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$162.45M, operating cash flow was -$146.72M and free cash flow was -$146.72M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$73.60M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $178.70M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Cost of revenue$0$0$0$0$0$0$0$8.24K
    Gross profit$0$0$0$0$0$0$0-$8.24K
    Research and development$157.70M$124.52M$86.14M$82.27M$51.10M$13.70M$3.92M$1.69M
    Operating income-$178.70M-$142.26M-$104.96M-$106.99M-$71.49M-$21.53M-$4.32M-$2.08M
    Net income-$162.45M-$129.47M-$96.66M-$104.79M-$71.10M-$22.12M-$4.32M-$2.20M
    EBITDAN/AN/A-$104.60M-$106.66M-$71.10M-$21.52M-$4.32M-$2.07M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$364.00K$0$0$0$1.88M
    Gross profit$0$0$0-$187.00K$0$0$0$182.00K$0$0$0$1.80M
    Operating income-$77.53M-$67.18M-$57.99M-$50.08M-$45.88M-$47.86M-$34.87M-$36.77M-$37.62M-$33.53M-$34.34M-$30.42M
    Net income-$73.60M-$63.20M-$53.09M-$46.06M-$42.22M-$43.78M-$30.39M-$33.57M-$34.55M-$30.38M-$30.97M-$26.77M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $4.12M by $44.18M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$533.43M$450.98M$276.94M$215.65M$295.94M$342.72M$132.00K$3.27M
    Current assets$515.45M$438.47M$266.51M$208.90M$290.69M$342.14M$103.00K$3.24M
    Cash and equivalents$48.30M$139.48M$68.54M$23.70M$13.81M$338.55M$68.00K$3.15M
    Total liabilities$54.87M$42.02M$23.05M$18.10M$11.38M$4.58M$10.73M$9.55M
    Short-term debt$1.12M$1.17M$988.00K$1.01M$931.00KN/AN/AN/A
    Long-term debt$3.00M$0N/AN/AN/AN/AN/AN/A
    Shareholder equity$478.56M$408.96M$253.90M$197.55M$284.57M$338.14M-$10.59M-$6.28M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$441.07M$486.58M$530.64M$533.43M$352.45M$382.00M$409.64M$450.98M$230.17M$254.56M$263.69M$276.94M
    Total liabilities$72.23M$56.01M$50.17M$54.87M$44.97M$36.77M$26.19M$42.02M$31.26M$27.39M$27.38M$23.05M
    Cash and equivalents$47.52M$48.60M$52.55M$48.30M$35.26M$52.47M$50.64M$139.48M$35.89M$16.89M$33.72M$68.54M
    Shareholder equity$368.84M$430.56M$480.48M$478.56M$307.49M$345.24M$383.45M$408.96M$198.91M$227.16M$236.32M$253.90M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$146.72M-$104.35M-$83.73M-$82.06M-$50.69M-$19.87M-$3.08M-$2.18M
    Capital expenditures$0$159.00K$0$363.00K$1.57M$56.00K$56.00K$56.00K
    Free cash flow-$146.72M-$104.51M-$83.73M-$82.43M-$52.27M-$19.92M-$3.14M-$2.23M
    Dividends paidN/AN/AN/AN/AN/A$3.09MN/AN/A
    Investing cash flow-$155.76M-$93.53M-$4.85M$91.48M-$275.44M-$56.00K-$56.00K-$56.00K
    Financing cash flow$211.30M$268.82M$133.41M$476.00K$1.39M$358.40M$358.40M$5.25M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$47.11M-$45.90M-$45.99M-$38.33M-$34.53M-$29.88M-$43.98M-$26.28M-$27.02M-$27.55M-$23.50M-$18.48M
    Capital expenditures$900.00KN/A$0$0$0$0$0$0$159.00K$6.00K$153.00K$0
    Free cash flow-$48.01MN/A-$45.99M-$38.33M-$34.53M-$29.88M-$43.98M-$26.28M-$27.18M-$27.56M-$23.65M-$18.48M
    Last 12 quarters

    Frequently Asked Questions About OLMA

    What is Olema Pharmaceuticals' annual revenue?

    Olema Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Olema Pharmaceuticals profitable?

    No. Olema Pharmaceuticals reported net income of -$162.45M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does OLMA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$146.72M minus capital expenditures of $0 produced free cash flow of -$146.72M.

    How much debt does Olema Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $3.00M, short-term debt of $1.12M and cash and equivalents of $48.30M.